Burden of influenza B virus infection and considerations for clinical management
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier B.V.
Abstract
Influenza B viruses cause significant morbidity and mortality, particularly in children, but the awareness of their impact is often less than influenza A viruses partly due to their lack of pandemic potential. Here, we summarise the biology, epidemiology and disease burden of influenza B, and review existing data on available antivirals for its management. There has long been uncertainty surrounding the clinical efficacy of neuraminidase inhibitors (NAIs) for influenza B treatment. In this article, we bring together the existing data on NAIs and discuss these alongside recent large randomised controlled trial data for the new polymerase inhibitor baloxavir in high-risk influenza B patients. Finally, we offer considerations for the clinical management of influenza B, with a focus on children and high-risk patients where disease burden is highest. © 2020
Description
Keywords
Antiviral, Baloxavir, Clinical management, Influenza b, Nai, Oseltamivir, Antiviral agents, Child, Clinical trials, phase iii as topic, Cost of illness, Dibenzothiepins, Disease management, Drug resistance, viral, Enzyme inhibitors, Humans, Influenza b virus, Influenza, human, Morpholines, Pandemics, Pyridones, Triazines, Antivirus agent, Baloxavir marboxil, Favipiravir, Laninamivir, Laninamivir octanoate, Peramivir, Pimodivir, Zanamivir, Dibenzothiepin derivative, Dipyrone, Enzyme inhibitor, Morpholine derivative, Triazine derivative, Antiviral activity, Antiviral resistance, Antiviral therapy, Clinical study, Disease burden, Disease course, Drug efficacy, Drug megadose, High risk patient, High risk population, Human, Immunocompromised patient, Pediatric patient, Priority journal, Review, Single drug dose, Drug effect, Influenza, Pandemic, Pathogenicity, Phase 3 clinical trial (topic)